Market Research Logo

Colorectal Cancer Diagnostic Market with Focus on DNA-Based Tests: Industry Analysis & Outlook (2018-2025)

Colorectal Cancer Diagnostic Market with Focus on DNA-Based Tests: Industry Analysis & Outlook (2018-2025)

Colorectal cancer, also known as bowel cancer and colon cancer, is the development of the cancer in the colon or rectum. A cancer is the abnormal growth of the cells that have the ability to invade or spread to the other parts of the body. Colorectal cancer begins when the healthy cells in the lining of the colon or rectum changes and grows out of control, forming a mass called tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread. These changes usually take years to develop.

Screening for colorectal cancer is effective not only for early detection but also for prevention. Diagnosis of colorectal cancer through screening tends to occur 2-3 years before diagnosis of cases with symptoms. CRC Screening is broadly divided into Structural Examination and Stool Tests. Structural examination is further divide into Flexible Sigmoidography, Colonoscopy and Computed Tomographic Colonography, whereas Stool Tests are divided into Occult blood and DNA tests.

Colorectal cancer diagnostic market is expected to grow in future due to increasing disposable income, increasing ageing population and cancer incidences and rising healthcare expenditure. Key trends of this market include launch of branded and advanced diagnosis and technology innovation. However, there are some factors which can hinder the market growth including stringent legal norms, high cost, need for high quality of screening process and dearth of expertise.

The report “Colorectal Cancer Diagnostics Market with Focus on DNA-based Tests: Industry Analysis & Outlook (2018-2025)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and Asia. The report profiles the key players of the market including Epigenomics, Exact Sciences Corporation, VoilitionRx Ltd and Quest Diagnostics.


1. Introduction
1.1 Colorectal Cancer
1.2 Diagnosis
Table 1: Types of CRC Screening
1.3 Treatment
2. Market Overview
2.1 Global Colorectal Cancer Incidences Forecast
Table 2: Global Colorectal Cancer Incidences Forecast (2017-2022)
2.2 CRC Death Averted per 1,000 Individuals Screened
Table 3: CRC Death Averted per 1,000 Individuals Screened (2017)
2.3 Distribution of Colorectal Cases and Relative Survival
Table 4: Distribution of Colorectal Cancer Cases and Relative Survival
2.4 Colorectal Cancer Screening Test Types
Table 5: Types of Colorectal Cancer Screening Tests
3. The U.S. Colorectal Cancer Screening Market
3.1 The U.S. CRC Screening Eligible Patient Volume Forecast
Table 6: The U.S. CRC Screening Eligible Patient Volume Forecast (2018-2025)
3.2 The U.S. CRC Screening Receiving Patient Volume Forecast
Table 7: The U.S. CRC Screening Receiving Patient Volume Forecast (2018-2025)
3.3 The U.S. CRC Screening Test Market Volume Forecast
Table 8: The U.S. CRC Screening Test Market Volume Forecast (2017-2022)
3.4 The U.S. CRC Screening Market Volume by Type
Table 9: The U.S. CRC Screening Market Volume by Type (2017)
3.4.1 The U.S. CRC Colonoscopies Volume Forecast
Table 10: The U.S. CRC Colonoscopies Volume Forecast (2017-2022)
3.4.2 The U.S. CRC Sigmoidoscopies Volume Forecast
Table 11: The U.S. CRC Sigmoidoscopies Volume Forecast (2017-2022)
3.4.3 The U.S. CRC FOBT Volume Forecast
Table 12: The U.S. CRC FOBT Volume Forecast (2017-2022)
3.4.4 The U.S. CRC Stool Based DNA Test Volume Forecast
Table 13: The U.S. CRC Stool Based DNA Test Volume Forecast (2017-2022)
3.5 The U.S. CRC Screening Test Product Market
3.5.1 The U.S. CRC Frontline Screening Tested Patient Volume Forecast
Table 14: The U.S. CRC Frontline Screening Tested Patient Volume Forecast (2021-2025)
3.5.2 The U.S. CRC Frontline Screening Test Sales Forecast by Value
Table 15: The U.S. CRC Frontline Screening Test Sales Forecast by Value (2021-2025)
3.5.3 The U.S. CRC Cologuard Screening Test Sales Forecast
Table 16: The U.S. CRC Cologuard Screening Test Sales forecast (2017-2022)
3.5.4 The U.S. CRC Epi proColon Screening Test Sales Value Forecast
Table 17: The U.S. CRC Epi proColon Screening Test Sales Value forecast (2017-2022)
4. Europe Colorectal Cancer Screening Market
4.1 Europe CRC Screening Eligible Patient Volume Forecast
Table 18: Europe CRC Screening Eligible Patient Volume Forecast (2018-2025)
4.2 Europe CRC Screening Eligible Patient Volume by Country
4.2.1 The UK CRC Screening Eligible Patient Volume Forecast
Table 19: The UK CRC Screening Eligible Patient Volume Forecast (2018-2025)
4.2.2 Sweden CRC Screening Eligible Patient Volume Forecast
Table 20: Sweden CRC Screening Eligible Patient Volume Forecast (2018-2025)
4.2.3 Denmark CRC Screening Eligible Patient Volume Forecast
Table 21: Denmark CRC Screening Eligible Patient Volume Forecast (2018-2025)
4.2.4 Netherland CRC Screening Eligible Patient Volume Forecast
Table 22: Netherland CRC Screening Eligible Patient Volume Forecast (2018-2025)
4.3 Europe CRC Screening Receiving Patient Volume Forecast
Table 23: Europe CRC Screening Receiving Patient Volume Forecast (2018-2025)
4.4 Europe CRC Screening Test Product Market
4.4.1 Europe CRC Frontline Screening Tested Patient Volume Forecast
Table 24: Europe CRC Frontline Screening Tested Patient Volume Forecast (2019-2025)
4.4.2 Europe CRC Frontline Screening Test Sales Forecast by Value
Table 25: Europe CRC Frontline Screening Test Sales Forecast by Value (2019-2025)
4.4.3 Europe CRC Triage Screening Tested Patient Volume Forecast
Table 26: Europe CRC Triage Screening Tested Patient Volume Forecast (2018-2025)
4.4.4 Europe CRC Triage Screening Test Sales Forecast by Value
Table 27: Europe CRC Triage Screening Test Sales Forecast by Value (2018-2025)
5. Asia Colorectal Cancer Screening Market
5.1 Asia CRC Screening Eligible Patient Volume Forecast
Table 28: Asia CRC Screening Eligible Patient Volume Forecast (2018-2025)
5.2 Asia CRC Screening Test Product Market
5.2.1 Asia CRC Frontline Screening Tested Patient Volume Forecast
Table 29: Asia CRC Frontline Screening Tested Patient Volume Forecast (2019-2025)
5.2.2 Asia CRC Frontline Screening Test Sales Forecast by Value
Table 30: Asia CRC Frontline Screening Test Sales Forecast by Value (2019-2015)
5.2.3 Asia CRC Triage Screening Test Sales Forecast by Value
Table 31: Asia CRC Triage Screening Test Sales Forecast by Value (2019-2025)
5.2.4 Asia CRC Triage Screening Tested Patient Volume Forecast
Table 32: Asia CRC Triage Screening Tested Patient Volume Forecast (2019-2025)
6. Market Dynamics
6.1 Growth Drivers
6.1.1 Increasing Disposable Income
Table 33: Global GNI per Capita (2013-2017)
6.1.2 Acceleration of Ageing Population and Cancer Incident Cases
Table 34: Global Ageing Population above 65 Years (2013-2017)
6.1.3 Rising Healthcare Expenditure
Table 35: Global Healthcare Expenditure Per Capita (2013-2017)
6.2 Key Trends
6.2.1 Launch of Branded and Advanced Diagnostic Tests
6.2.2 Technology Innovation
6.3 Challenges
6.3.1 Stringent Legal Norms
6.3.2 High Cost and Alternative Treatments
6.3.3 Need for High Quality of Screening Process
6.3.4 Dearth of Expertise
7. Competition
7.1 Global Market
7.1.1 Revenue Comparison of Key Players
Table 36: Revenue Comparison of Key Players (2017)
7.1.2 DNA based CRC Screening Tests Comparison
Table 37: DNA based CRC Screening Tests Comparison (2017)
8. Company Profiles
8.1 Exact Sciences Corporation
8.1.1 Business Overview
8.1.2 Financial Overview
Table 38: Exact Sciences Corporation Sales and Net Earnings (2013-2017)
8.1.3 Business Strategies
Table 39: Exact Sciences Corporation Research and Development Expenditure (2015-2017)
Table 40: Exact Sciences Corporation Media and Advertisement Expenditure (2015-2017)
8.2 Volition Rx Ltd.
8.2.1 Business Overview
8.2.2 Financial Overview
Table 41: Volition Rx Ltd. Net loss (2013-2017)
8.2.3 Business Strategies
Table 42: Volition Rx Ltd. Research and Development Expenditure (2015-2017)
Table 43: Volition Rx Ltd. Media and Advertisement Expenditure (2016-2017)
8.3 Epigenomics AG
8.3.1 Business Overview
Table 44: Epigenomics Revenue by Segment (2017)
8.3.2 Financial Overview
Table 45: Epigenomics Revenue and Net Loss (2013-2017)
8.3.3 Business Strategies
Table 46: Epigenomics Research and Development Expenditure (2016-2017)
8.4 Quest Diagnostics
8.4.1 Business Overview
Table 47: Quest Diagnostics Revenue by Segment (2017)
8.4.2 Financial Overview
Table 48: Quest Diagnostics Revenue and Net Income (2013-2017)
8.4.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report